News
- Kindred Biosciences Announces Third Quarter 2018 Financial ResultsNovember 7, 2018 - 4:01 p.m.
- Kindred Biosciences Announces Positive Results from Pilot Effectiveness Study of its Fully Caninized IL-31 Antibody for the Treatment of Atopic Dermatitis in Dogs and Issuance of U.S. PatentOctober 30, 2018 - 4:02 p.m.
- Kindred Biosciences to Announce Third Quarter 2018 Financial ResultsOctober 24, 2018 - 8:31 a.m.
Kindred Biosciences' First Quarter 2019 Financial Results (Live)
05/09/19 at 4:30 p.m. ET
Thursday, May 9, 2019 4:30 p.m. ET
Kindred Biosciences Announces Third Quarter 2018 Financial Results
November 7, 2018
SAN FRANCISCO, Nov. 7, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: K...
Kindred Biosciences Announces Positive Results from Pilot Effectiveness Study of its Fully Caninized IL-31 Antibody for the Treatment of Atopic Dermatitis in Dogs and Issuance of U.S. Patent
October 30, 2018
- Statistically significant reduction in pruritus versus placebo was achieved ac...
Kindred Biosciences to Announce Third Quarter 2018 Financial Results
October 24, 2018
Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time / 1:30 p.m...
Kindred Biosciences Elects Denise Bevers to its Board of Directors and Promotes Her to President
October 23, 2018
SAN FRANCISCO, Oct. 23, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: ...
Kindred Biosciences to Present at Cantor Global Healthcare Conference and Ladenburg Thalmann 2018 Healthcare Conference
September 17, 2018
SAN FRANCISCO, Sept. 17, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ:...
Kindred Biosciences to Participate in the CL King 16th Annual Best Ideas Conference, Lake Street Capital Markets 2nd Annual Best Ideas Growth Conference and LD Micro San Francisco Summit
August 30, 2018
SAN FRANCISCO, Aug. 30, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: ...
Kindred Biosciences to Participate in the B. Riley FBR Annual Healthcare Conference
August 21, 2018
SAN FRANCISCO, Aug. 21, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: ...
Kindred Biosciences Announces Second Quarter 2018 Financial Results
August 9, 2018
SAN FRANCISCO, Aug. 9, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: K...
Kindred Biosciences to Announce Second Quarter 2018 Financial Results
July 16, 2018
Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time / 1:30 p.m...
Kindred Biosciences Announces Commercial Availability of Mirataz® (mirtazapine transdermal ointment) to Veterinarians in the United States
July 9, 2018
SAN FRANCISCO, July 9, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASD...
Kindred Biosciences Announces Exercise of Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
June 25, 2018
SAN FRANCISCO, June 25, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: ...
Kindred Biosciences Announces the Termination of Its At-The-Market Equity Offering Program
June 20, 2018
SAN FRANCISCO, June 20, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: ...
Kindred Biosciences Announces Pricing of Public Offering
June 20, 2018
SAN FRANCISCO, June 20, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: ...
Kindred Biosciences Announces Proposed Public Offering of Common Stock
June 19, 2018
SAN FRANCISCO, June 19, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: ...
KindredBio Announces Positive Results from Pilot Effectiveness Study of KIND-014 for the Treatment of Gastric Ulcers in Horses
May 30, 2018
SAN FRANCISCO, May 30, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: K...
Kindred Biosciences to Present at Jefferies 2018 Global Healthcare Conference and 8th Annual LD Micro Invitational Conference
May 29, 2018
SAN FRANCISCO, May 29, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: K...
Kindred Biosciences to Present at Stifel 2018 Dental & Veterinary Conference
May 24, 2018
SAN FRANCISCO, May 24, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: K...
Kindred Biosciences Announces First Quarter 2018 Financial Results
May 8, 2018
SAN FRANCISCO, May 8, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KI...
Kindred Biosciences Receives FDA Approval of Mirataz™ (mirtazapine transdermal ointment) for the Management of Weight Loss in Cats
May 7, 2018
SAN FRANCISCO, May 7, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KI...
Kindred Biosciences Announces the Appointment of Dr. Ernest Mario and Dr. Joseph McCracken to its Board of Directors
April 25, 2018
SAN FRANCISCO, April 25, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ:...
Kindred Biosciences Provides Updates on Pending Drug Approvals
April 24, 2018
SAN FRANCISCO, April 24, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ:...
Kindred Biosciences to Announce First Quarter 2018 Financial Results
April 18, 2018
Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time / 1:30 p.m...
Kindred Biosciences to Present at the Oppenheimer 28th Annual Healthcare Conference
March 8, 2018
SAN FRANCISCO, March 8, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: ...
Kindred Biosciences Announces Fourth Quarter and Full Year 2017 Financial Results
March 1, 2018
SAN FRANCISCO, March 1, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: ...
Kindred Biosciences to Announce Fourth Quarter and Year-End 2017 Financial Results
February 15, 2018
Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time / 1:30 p.m...
Kindred Biosciences to Participate in the Bank of America Merrill Lynch Animal Health Summit
February 13, 2018
SAN FRANCISCO, Feb. 13, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: ...